Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 754 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian... April 21, 2026 New “Microwave Mammography” Promises to be Safer, More Accurate, and Pain-Free September 19, 2019 FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer October 15, 2024 A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... May 9, 2023 Load more HOT NEWS Meet the teams tackling 5 challenges in children’s and young people’s... Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... High-Deductible Health Plans Linked to Delayed Diagnosis and Treatment of Breast... EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+...
